¹³¹I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future.

ABSTRACT:

Background

The prognosis of relapsed/refractory (R/R) neuroblastoma (NB) is still dismal. The role of iodine-131 meta-iodobenzylguanidine (¹³¹I-mIBG) treatment as a tool to reduce tumour burden before novel immunotherapies is not defined.

Patients and methods

Patients with R/R NB were included in a prospective observational study based on two infusions of ¹³¹I-mIBG plus melphalan (110 mg/m²), supported by autologous haematopoietic stem cell rescue. The activity of the first administration was 444 MBq (12 mCi/kg), while the second dose was modulated to reach a whole-body absorbed dose of 4 Gy. The International Neuroblastoma Response Criteria (INRC) were used for response.

Results

Twenty-six patients with a median age of 5.9 years (rang

SUBMITTER: De Ioris MA 

PROVIDER: S-EPMC12002777 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature